Abstract
Objective: The goal of this report is to describe the on going strategies, successes, challenges and solutions for recruitment in this multi-center, phase II chemoprevention trial targeting men at high risk for prostate cancer. Methods: We developed and implemented a multi-center clinical trial in institutions with supportive infrastructure, lead by a recruitment team of experienced and committed physicians and clinical trial staff, implementing multi-media and community outreach strategies to meet recruitment goals. Screening logs were reviewed to identify trends as well as patient, protocol and infrastructure -related barriers impacting accrual and revisions to protocol implemented. Results: Between January 2008 and February 2011 a total of 3547 individuals were prescreened with 94% (n= 3092) determined to be ineligible based on diagnosis of cancer or benign biopsy results. Of these, 216 were considered eligible for further screening with 52% (n=113) declining to participate due to patient related factors and 14% (n=29) eliminated due to protocol-related criteria for exclusion. Ninety-four (94) subjects consented to participate with 34% of these subjects (n=74) meeting all eligibility criteria to be randomized to receive study agent or placebo. Across all sites, 99% of the recruitment of subjects in this clinical trial is via physician recruitment and referral with less than 1% responding to other recruitment strategies. Conclusion: A contemporary approach to subject recruitment and frequent evaluation is needed to assure responsiveness to emerging challenges to accrual and the evolving scientific literature. A focus on investing on improving systems for physician recruitment may be key to meeting recruitment target in chemoprevention trials.
Original language | English (US) |
---|---|
Pages (from-to) | 279-285 |
Number of pages | 7 |
Journal | Contemporary Clinical Trials |
Volume | 33 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2012 |
Bibliographical note
Funding Information:The research study was funded by the National Institute of Health-National Cancer Institute R01 CA12060-01A1 .
Keywords
- Chemoprevention trials
- Clinical trials
- Green tea polyphenols
- Prostate cancer
- Recruitment
- Screening
- Trial accrual